Abstract
The limited effectiveness of orlistat, an inhibitor of gastrointestinal lipases, in inhibiting fat digestion is not completely understood. Therefore we studied the effect of orally and duodenally administered orlistat on gastric emptying, cholecystokinin (CCK) secretion, and gallbladder contraction. In healthy males, gastric emptying of solids and fat were quantified scintigraphically, gallbladder contraction by ultrasound and CCK release by radioimmunoassay. Three studies were performed: (1) oral and (2) duodenal orlistat with a fat-containing meal, and (3) duodenal orlistat with a fat-free meal. Gastric emptying rates of solids and fat (T50% accelerated by 16 and by 22%, p< 0.05, respectively) were significantly faster after duodenal perfusion of orlistat; gallbladder contraction and CCK release were reduced under these conditions (p < 0.005, respectively). With oral orlistat no significant effect was documented on these parameters. We conclude that fat hydrolysis is essential in the regulation of fat-induced gastric emptying and gallbladder contraction.
Journal Section:
Original Paper
References
1.
Mayer EA: The physiology of gastric storage and emptying; in Johnson LR (ed): Physiology of the Gastrointestinal Tract. New York, Raven Press, 1994, pp 929–976.
2.
Solomon TE: Control of exocrine pancreatic secretion; in Johnson LR (ed): Physiology of the Gastrointestinal Tract. New York, Raven Press, 1994, pp 1499–1530.
3.
Meyer JH, Mayer EA, Jehn D, Gu Y, Fink AS, Fried M: Gastric processing and emptying of fat. Gastroenterology 1986;90(5 Pt 1):1176–1187.
[PubMed]
4.
Hildebrand P, Beglinger C, Gyr K, Jansen JB, Rovati LC, Zuercher M, et al: Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. J Clin Invest 1990;85:640–646.
[PubMed]
5.
Beglinger C, Hildebrand P, Adler G, Werth B, Luo H, Delco F, et al: Postprandial control of gallbladder contraction and exocrine pancreatic secretion in man. Eur J Clin Invest 1992;22:827–834.
[PubMed]
6.
Matzinger D, Gutzwiller JP, Drewe J, Orban A, Engel R, D’Amato M, et al: Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. Am J Physiol 1999;277:R1718–R1724.
7.
Matzinger D, Degen L, Drewe J, Meuli J, Duebendorfer R, Ruckstuhl N, et al: The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans. Gut 2000;46:688–693.
[PubMed]
8.
Tso P: Intestinal lipid absorption; in Johnson LR (ed): Physiology of the Gastrointestinal Tract. New York, Raven Press, 1994, pp 1867–1908.
9.
McLaughlin JT, Lomax RB, Hall L, Dockray GJ, Thompson DG, Warhurst G: Fatty acids stimulate cholecystokinin secretion via an acyl chain length-specific, Ca2+-dependent mechanism in the enteroendocrine cell line STC-1. J Physiol (Lond) 1998;513:11–18.
10.
Guimbaud R, Moreau JA, Bouisson M, Durand S, Escourrou J, Vaysse N, et al: Intraduodenal free fatty acids rather than triglycerides are responsible for the release of CCK in humans. Pancreas 1997;14:76–82.
[PubMed]
11.
Hildebrand P, Petrig C, Burckhardt B, Ketterer S, Lengsfeld H, Fleury A, et al: Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release. Gastroenterology 1998;114:123–129.
[PubMed]
12.
Maas MI, Hopman WP, Gelder BV, Jacobs M, De Haan AF, Katan MB, et al: Does intraduodenal administration of sucrose polyester (Olestra) cause satiation in humans? Appetite 1999;33:195–208.
[PubMed]
13.
Meyer BM, Werth BA, Beglinger C, Hildebrand P, Jansen JB, Zach D, et al: Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet 1989;2:12–15.
[PubMed]
14.
Schwizer W, Asal K, Kreiss C, Mettraux C, Borovicka J, Remy B, et al: Role of lipase in the regulation of upper gastrointestinal function in humans. Am J Physiol 1997;273:G612–G620.
15.
Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C, et al: Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 1991;101:503–511.
[PubMed]
16.
Liddle RA, Morita ET, Conrad CK, Williams JA: Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 1986;77:992–996.
[PubMed]
17.
Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Coker LD, Turnbull TA, et al: Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J Clin Invest 1989;84:1220–1225.
[PubMed]
18.
Camilleri M, Colemont LJ, Phillips SF, Brown ML, Thomforde GM, Chapman NJ, et al: Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989;257:G284–G90.
19.
Stivland T, Camilleri M, Vassallo M, Proano M, Rath D, Brown M, et al: Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991;101:107–115.
[PubMed]
20.
Cunningham KM, Baker RJ, Horowitz M, Maddox AF, Edelbroek MA, Chatterton BE: Use of technetium-99m(V)thiocyanate to measure gastric emptying of fat. J Nucl Med 1991;1991:878–881.
21.
Degen LP, von Flue MO, Collet A, Hamel C, Beglinger C, Harder F: Ileocecal segment transposition does not alter whole gut transit in humans. Ann Surg 1997;226:746–752.
[PubMed]
22.
Sachs L: Angewandte Statistik. Berlin, Springer, 1984.
23.
McLaughlin J, Grazia Lucà M, Jones MN, D’Amato M, Dockray GJ, Thompson DG: Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility. Gastroenterology 1999;116:46–53.
[PubMed]
24.
Meyer JH, Elashoff JD, Domeck M, Levy A, Jehn D, Hlinka M, et al: Control of canine gastric emptying of fat by lipolytic products. Am J Physiol 1994;266:G1017–G1035.
25.
Ackroff K, Sclafani A: Effects of the lipase inhibitor orlistat on intake and preference for dietary fat in rats. Am J Physiol 1996;271:R48–R54.
26.
James WP, Avenell A, Broom J, Whitehead J: A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 1997;21(suppl 3):S24–S30.
[PubMed]
27.
Lekkerkerker JF, Diemont WL, Koopmans PP: Orlistat and weight loss (letter). Lancet 1998;352:1473–1474.
[PubMed]
28.
Hildebrand P, Petrig C, Burckhardt B, Ketterer S, Lengsfeld H, Fleury A, et al: Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release. Gastroenterology 1998;114:123–129.
[PubMed]
29.
Carriere F, Barrowman JA, Verger R, Laugier R: Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 1993;105:876–888.
[PubMed]
30.
Carriere F, Renou C, Lopez V, De Caro J, Ferrato F, Lengsfeld H, et al: The specific activities of human digestive lipases measured from the in vivo and in vitro lipolysis of test meals. Gastroenterology 2000;119:949–960.
[PubMed]
31.
Carriere F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato F, et al: Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001;281:G16–G28.
[PubMed]
32.
Meyer JH, Gu YG, Jehn D, Doty JE: Factors that affect the performance of lipase on fat digestion and absorption in a canine model of pancreatic insufficiency. Pancreas 1994;9:613–623.
[PubMed]
33.
Feinle-Bisset C, Patterson M, Ghatei MA, Bloom SR, Horowitz M: Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab 2005;289:E948–E953.
34.
Froehlich F, Hartmann D, Guezelhan C, Gonvers JJ, Jansen JB, Fried M: Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996;41:2404–2408.
[PubMed]
35.
Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA: Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985;75:1144–1152.
[PubMed]
© 2006 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
